Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2012

View Archived Issues

AEOL-10150 demonstrates neuroprotective effects in rat model

Computational model includes all molecular components and interactions of pathogen's life cycle

Phase I/II trial assesses ROSE-010 in IBS-C

Vivalis synthesizes new candidate hepatitis therapies

New colimycin biosynthesis genes patented

Zetonna launched in U.S.

Omeros discovers key proteins in MASP-2 program

Novel protein kinase inhibitors disclosed by Leo Pharma

Phase I ALS-2200 data disclosed

Chinese researchers present new candidate cancer drugs

Novel tubulin polymerization inhibitors patented by group in Taiwan

U.S. university patents novel mGlu5 receptor modulators

Torii Pharmaceutical launches new Mitizax trials in Japan

La Jolla Pharmaceutical gives update on GCS-100 plans

Transgene and Tasly Pharmaceutical form joint venture

APP gene variant linked to reduced cognitive decline

FDA accepts Zelrix NDA resubmission for filing

CytoDyn to acquire antibody inhibiting HIV entry

Oncobiologics to utilize Xoma antibody technology platform

Second phase of malaria grant awarded to PolyMedix

MolecularMD seeks approval for companion diagnostic test

GenSpera's lead product clear to advance to phase II testing

Clinical proof of concept demonstrated for SCY-635

Recruitment complete in pivotal CRUISE trials

EryDel product receives orphan drug status for ataxia telangiectasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...